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Abstract
Nanoparticles (NPs) have emerged as a potential tool to improve cancer treatment. Among the proposed uses in imaging
and therapy, their use as a drug delivery scaffold has been extensively highlighted. However, there are still some
controversial points which need a deeper understanding before clinical application can occur. Here the use of gold
nanoparticles (AuNPs) to detoxify the antitumoral agent cisplatin, linked to a nanoparticle via a pH-sensitive coordination
bond for endosomal release, is presented. The NP conjugate design has important effects on pharmacokinetics, conjugate
evolution and biodistribution and results in an absence of observed toxicity. Besides, AuNPs present unique opportunities
as drug delivery scaffolds due to their size and surface tunability. Here we show that cisplatin-induced toxicity is clearly
reduced without affecting the therapeutic benefits in mice models. The NPs not only act as carriers, but also protect the
drug from deactivation by plasma proteins until conjugates are internalized in cells and cisplatin is released. Additionally,
the possibility to track the drug (Pt) and vehicle (Au) separately as a function of organ and time enables a better
understanding of how nanocarriers are processed by the organism.
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Introduction
1. NanoOncology
The global death rate from cancer has declined only marginally
over the past several decades, in contrast to dramatic reversals in
death rates from heart disease, stroke, and infectious disease over
the same time period [1]. In this context, nanotechnology emerges
as a ‘‘disruptive technology’’ with a great potential to contribute to
improve cancer treatment by generating new diagnostic and
therapeutic products [2–5]. Thus, nanotechnology has been
proposed to enable researchers to combine a series of advances;
creating nanosized particles that may contain drugs designed to
kill tumors together with targeting compounds designed to home
in on malignancies [6–8], and imaging agents designed to light up
even the earliest stage of cancer or monitor its treatment [9]. Thus,
functionalized nanoparticles could deliver multiple therapeutic
agents to tumor sites in order to simultaneously attack multiple
points in the pathways involved in cancer. However, despite the
plethora of nanoparticles (NP), organic or inorganic, and
conjugated chemotherapeutic agents which have shown promising
results in vitro, the precise behavior of these conjugates in vivo is still
rather unknown, with controversy about disparities between the in
vitro and in vivo results or results from different laboratories. There
are indications that small modifications of the nature of the
conjugate have a strong influence on conjugate interactions [10],
protein corona formation [11,12], aggregation [13], degradation
[14], and consequently biological behavior during the full life cycle
of the conjugate inside the body [15]. By attaching the drug to the
NP, its physicochemical fate is modified. Thus, nanocarriers can
strongly contribute to modifications in pharmacokinetics (Table 1)
and biodistribution, by leading the drug through different
pathways depending on the physicochemical properties of the
nanocarrier (e.g., size and surface charge), which is especially
appealing in the case of very toxic drugs [16,17]. Inside the body,
pores smaller than 1 nm have been reported in the tight junctions
on certain continuous capillaries (including the central nervous
system, i.e., blood-brain barrier, placenta and testis barrier) while
continuous capillaries (muscle, lung, skin) have pores of 6 nm [18].
Fenestrated capillaries (kidney, intestine, some endocrine and
exocrine glands) have pores up to 50–60 nm, usually closed by a
diaphragm [18]. Finally, discontinuous capillaries (liver, spleen,
bone marrow) have pores between 100–1000 nm, which allow the
passage of macromolecules between plasma and interstitium [18].
Thus, small molecules (below 6 nm, the majority of drugs) leak in
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and out from the blood vessels and are rapidly (in minutes) cleared
from blood via the kidneys [19] while the passive transport of
macromolecules through these porous is negligible. Thus a NP
sized between 6–40 nm may follow protein paths to finally
accumulate in organs of the mononuclear phagocyte system,
especially the liver and spleen, as do proteins and protein
aggregates [20], while larger sizes of NP are easily recognized by
the immune system and also end up in liver and spleen but within
a shorter time [21]. It is worth noting here that blood vessel
permeability changes in diseases such as inflammation and cancer
[22]. In cancer, the rapid growth of tumor results in leaky vessels.
These fenestrated vessels allow macromolecules and NPs to
permeate through the tumor. In addition, the nanoparticles are
retained due to the lack of a functional lymphatic system. This
effect (Enhanced Permeability and Retention effect, EPR) is widely
reported in the literature [23,24] and has been exploited to
passively accumulate nanocarriers in tumors [4]. Other described
pathways are more complex and include the use of migrating
macrophages as transporters of NPs and drugs [25]. In all cases,
surface modifications allow the modification of this size-dependent
fate, for example, by making small NPs recognizable by the
immune system [26] or shielding the large ones by means of
chemical modification such as pegylation [27].
Beyond oncology, small inorganic NPs the size of a small
protein (5–30 nm) are making their way towards the clinic: AuNPs
are used in cell imaging [28], targeted drug delivery [29,30], as
photothermal agents for hyperthermia [31], and in other proposed
diagnoses and therapies [32]. AgNPs display a biocidal effect [33]
that is currently applied in commercial products such as hospital
equipment and devices. Magnetic NPs are present in various
biomedical applications, e.g., the early detection of cancer,
diabetes, and atherosclerosis [34]. CeO2NPs are being used in
biomedicine as an antioxidant to treat disorders caused by oxygen
radicals, such as retinal degeneration [35] or cardiomyopathy
[36]. Non-inorganic nanomaterials have also reached the clinics,
e.g., Doxil, which is a liposomal formulation (hundreds of
nanometers in size, biocompatible and biodegradable) of doxoru-
bicin that increases the solubility of the active ingredient and
modifies the dosing by sustaining it over time.
2. The Case of Cisplatin
Platinum compounds (Figure 1) are a paradigm in anticancer
drugs. Cisplatin or cis-diamminedichloroplatinum(II),
[PtCl2(NH3)2], was originally synthesized in 1845, but not until
1970 was its antitumor activity established [37]. Today cisplatin is
used to treat various types of cancers (i.e., non-small-cell lung
cancer, ovarian cancer, germ cell tumors, osteosarcomas, etc.),
with a cure rate as high as 90% in testicular cancer [38]. The
platinum complex reacts in vivo to form adducts with DNA, which
ultimately trigger apoptosis [39]. It has been proven that, after
both passive and active cellular uptake, cisplatin may react with
the N7 atom of purine bases in DNA [38]. However, chronic
cisplatin usage results in resistance via several possible mechanisms
including increased interactions with metallothioneins and gluta-
thione, which deactivate the drug, as well as increased DNA repair
and/or cisplatin efflux [40]. To counteract resistance, which
lowers the efficiency of cisplatin significantly, very high systemic
doses of cisplatin should be administered. Unfortunately, such high
doses of cisplatin result in severe systemic toxicity and poor patient
compliance, including nausea/vomiting, renal toxicity, gastroin-
testinal toxicity, peripheral neuropathy, asthenia, and ototoxicity,
which thus limit its clinical use [40,41]. Of all the toxicities
induced by cisplatin, nephrotoxicity is considered to be the dose-
limiting factor [39]. Such side effects make it impossible to achieve
the full benefit of the treatment in a large number of patients [42].
In humans, cisplatin treatment generally involves series of
intravenous injections administered every 3–4 weeks at a dose of
50–120 mg/m2 (1.2–2.7 mg kg21). In addition to the undesired
side effects, there is also a loss of drug activity in the body
associated with poor circulation and poor delivery to the tumor, as
well as deactivation mechanisms that irreversibly alter the
chemistry of these molecules before reaching the tumor cells
[41]. Since its discovery, many attempts to find derivatives of
cisplatin have looked for both reduced side effects and modified
body distribution (in order to target different organs), rather than
improving cisplatin efficacy [40,43]. Here, second-generation
platinum drugs such as carboplatin and oxaliplatin represent an
improvement in some cancer treatments, for lung and colorectal
respectively, although the limitations observed for cisplatin have
not been entirely overcome [39,40].
3. Carrying Cisplatin
Recent efforts have been focused on targeting the tumor by
using drug delivery systems to avoid the organs to which cisplatin
is toxic. As the kidney is responsible for filtration and removal from
the blood of molecules smaller than 50 KDa, which corresponds
to molecular diameters of around 6 nm, any larger delivery vehicle
will divert the drug away from the kidney [19]. Additionally, NPs
accumulate in the tumor due to the EPR effect [23,24]; which is
known to be strongly size-dependent [44,45]. Therefore, when the
target is a solid tumor, nanometer-sized carriers are expected to be
passively accumulated on it. This case also applies when cisplatin is
bound to albumin. Up to 90% of the administrated cisplatin is
known to bind irreversibly to albumin [46] and then reach the
tumor by EPR; however, this form of cisplatin is inactive and has
no biological effect [47]. Thus, a properly designed nanocarrier
will not only transport the cisplatin to the tumor, but also protect it
against plasma deactivation.
In this context, approaches based on the encapsulation and
transport of cisplatin have emerged. Sterically stabilized polymeric
nanoparticles, which have excellent stability in plasma, a much
longer circulation time, better efficacy, and lower toxicity than free
cisplatin have been reported [6,7,48,49]. Such vehicles include
lipid capsules [50] or polymers as in ProlindacH, which has a
22 kDa hydroxypropylmethacrilamide copolymer as a backbone
and then a pH sensitive glycine chelator linker [51]. Other
Table 1. Key words in pharmacology.
Efficacy The ability of a drug to produce the desired therapeutic effect.
Efficiency The ability of a drug to produce few or no side effects while still performing its work.
Pharmacokinetics How the body affects a specific drug after administration. What the body does to the drug.
Pharmacodynamics The study of the biochemical and physiological effects of drugs on the body. What the drug does to the body.
doi:10.1371/journal.pone.0047562.t001
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examples include soluble CNTs [52], carbon nanohorns [53], and
Fe3O4 NPs [54]. Similarly, CytImmune Corp. is developing
AuNPs as a carrier for TNF-a and doxorubicin.AuNPs have been
recently proposed as scaffolds for cisplatin due to their controlled
and reproducible synthesis and conjugation to cisplatin as well as
the high loading of drug achieved [55]. Not only cisplatin, but
other Pt derivatives, such as Pt (IV) prodrugs, have also been
loaded on AuNPs with maintenance of the anticancer effect [56].
In closely related work, Ren et al. [57–59] reported the adsorption
of commercial cisplatin to gold colloids via ionic interactions. In
the case of adsorption via ionic interactions on the surface of the
nanomaterials, an uncontrolled rapid liberation of the drug is
observed as soon as the conjugates are dispersed in highly ionic
media such as serum [60]. In many of the reported systems,
colloidal stability in the working environment was an issue.
Materials and Methods
Ethics Statement
Mice were obtained from the Central Animal House of the
Santiago de Compostela University (USC), a registered animal
facility that maintains the animals under welfare and ethical
conditions complying with the European (86/609/CEE) and
Spanish (RD223/88 and OM 13/10/89) laws on laboratory
animal care and handling. In order to ameliorate suffering, mice
were anaesthetized with 2,2,2-tribromoethanol-2-methyl-2-buta-
nol (AvertineH, Sigma Aldrich) before xenotransplantation and
before receiving the different treatments reported here. After the
treatments, mice were euthanized by CO2 inhalation. The
biological work related to the results reported in this article had
the approval of the Ethical Committee of the USC and followed
the European and the Spanish legislations. 5 mL of blood were
obtained with informed written consent from a normal control
(JC, coauthor of the present work) and with approval from the
Ethical Committee of the USC.
Synthesis and Conjugation of AuNP-cisplatin
13 nm AuNPs were synthesized following a seeded-growth
approach and loaded with cisplatin in a two-step conjugation as
described in the literature [61] and in the Supplementary
Information (Text S1). There are several reasons for using this
synthesis: Control of the size is better than that achieved by
classical methods, the size distribution is very narrow and the
concentration of AuNPs is higher. Moreover, and according to our
experience, the reproducibility is far beyond that achievable by
using classic protocols. For more details, one can read our recent
work [61].
In vitro Stability and pH-dependent Release
17 mL of AuNP-cisplatin (2.7561014 NP ml –1) were added to
500 mL of human blood and gently mixed over 24 h. Colloidal
stability was assayed by using DLS and UV-Vis spectroscopy. The
UV-Vis spectra of all the AuNPs in the present work were
recorded from 300–800 nm at 0.5 nm intervals. When needed,
appropriate dilutions were performed to overcome the saturation
limit of absorbance. The release of cisplatin in physiological
conditions was performed in solutions consisting of 50 mM buffer
species, 120 mM NaCl, and 20% Foetal Bovine Serum (FBS).
Buffer species were HEPES for pH 7.6, MES for pH 6.2 and 4.4,
Glycine/HCl for pH 4.4 and 3.8 and Acetate for pH 4.4. 100 mL
of AuNP-cisplatin were added to 900 mL of the corresponding
buffered solution and mixed over differing lengths of time (2, 8, 24,
and 144 hours). AuNPs were removed by means of two
centrifugation steps (15 minutes, 35000 rcf). The amount of Pt
in the supernatant was analyzed by using ICP-MS.
Pt Cell Internalization and DNA Accumulation
The human lung carcinoma derived cell line A549 was obtained
from American Tissue Culture Collection (ATCC) and cultured in
a 1:1 mixture of Dulbeccos Modified Eagles Medium (DMEM,
Sigma-Aldrich) and Hams F-12 Medium (Sigma-Aldrich), supple-
mented of 10% (v/v) foetal bovine serum (FBS, GIBCO-
Invitrogen) and 1% (v/v) of L-glutamine, penicillin and strepto-
mycin solution (GPS, Sigma-Aldrich).To quantify Pt cell internal-
ization, 56105 cells were plated in 60-mm-diameter plates (Falcon)
and 24 hours later, medium was changed for treatments diluted in
culture medium: free cisplatin or cisplatin conjugated to AuNPs
(1.67 mg cisplatin mL21 in both cases). After 0.5, 1, 3, or 24 hours
of treatment, cells were trypsinized and centrifuged, supernatant
was removed and cells were resuspended in 0.5 mL 65% HNO3
(Merck). The amount of Pt was determined by using ICP-MS
(Bruker 820-MS). To quantify cisplatin bound to DNA, 106 cells
were treated as above and DNA extraction was performed by
using a commercial kit (QIAamp DNA Blood Mini Kit,
QIAGEN). DNA was finally resuspended in 200 mL of water.
Figure 1. Different platinum anticancer drugs approved by the FDA. The active part of each drug is drawn in black; in all cases it is
characterized by the presence of good leaving groups that will allow the Pt atom to bind the target. In red, the amines play a role in the modulation
of the activity and distribution of the drug. In the case of cisplatin, the equilibrium that spontaneously occurs inside the cell (where the chloride
concentration drops from 100 mM to 4 mM) is also shown.
doi:10.1371/journal.pone.0047562.g001
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This solution was used to determine both the amount of DNA and
Pt by using UV-Vis spectroscopy and ICP-MS, respectively.
TEM Cell Imaging
A549 cells were centrifuged for 15 min at 3000 rpm, fixed by
immersion for 45 min in 2.5% glutaraldehyde in sodium
cacodylate buffer (0.15 M, pH = 7.3), postfixed with 2% osmium
tetroxide in the same buffer, dehydrated, embedded in LRWhite
resin, Medium Grade, and sectioned. Sections were stained with
uranyl acetate and lead citrate and examined in a Zeiss 902
electron microscope (Carl Zeiss, F.R.G.) at 80 kV accelerating
voltage.
Biodistribution in Mice
In vivo biodistribution was measured by treating two groups of
12 female tumor-bearing SCID mice (three mice per point). All
mice received a single intraperitoneal (ip) dose of 4 mg cisplatin
kg–1 mice. At 0.5, 3, 6, and 24 h after the treatment, blood, heart,
lungs, kidney, brain, liver, spleen, ovaries, and tumor were
collected and weighed. To each organ, previously weighed, were
added 3 mL of 65% HNO3. The organs were then kept for 3 h at
room temperature in closed tubes and then for 24 h at 60uC.
Afterwards, 2 mL H2O2 were added to the sample and heated to
60uC. Finally H2O was added up to a final volume of 10 mL and
filtered with 0.22 mm filters. Blood serum was diluted 1:20 and
measured by using ICP-MS. Blood cells were resuspended in
6 mL of 65% HNO3 and 2 mL of H2O2 and heated in a
microwave oven (Milestone Ethos 1) as follows: 2 minutes at 85uC,
3.5 minutes at 135uC, and 15 minutes at 230uC. After cooling
down, H2O was added up to 10 mL final volume. The resulting
solutions of the above procedures were directly measured using
ICP-MS for the determination of Pt and Au (see Supplementary
Information for instrument operating details).
Kidney Histology
Proximal tubular degeneration was induced in mice by three
consecutive ip injections (days 0, 3, 6) of 5 mg cisplatin kg–1 mice.
The same dosage was applied in the case of AuNP-cisplatin, while
control mice received no treatment. Animals were sacrificed three
days after the last injection. Mouse kidneys and spleen were
immersion-fixed in 10% neutral buffered formalin for 24 h and
embedded in paraffin routinely. Sections (4 mm thick) were
mounted on microslides and stained with hematoxylin-eosin.
The specimens were examined and photographed using an
Olympus PROVIS AX70 microscope (Olympus, Tokyo, Japan)
equipped with an Olympus DP70 camera without prior knowledge
of the applied experimental protocol.
Therapeutic Efficacy in vivo
Mice with severe combined immunodeficiency (SCID) between
8 and 14 weeks-old were used to grow xenotransplant flank
tumors, one per mouse, by subcutaneous injection of 206106
A549 tumor cells. For monitoring, tumors were measured three
times weekly and the tumor volume was determined by the
formula V = (A6B2)/2, where A is the largest diameter and B is
the shortest diameter measured by caliper. After four to five weeks,
once the tumor volumes were $100 mm3 and mean tumor size
had reached 300 mm3, mice were divided into four groups of eight
mice for treatments, to minimize weight and tumor-size
differences. Tumor-bearing mice were treated by injection of
3 mg free cisplatin kg–1, 1.25 mg conjugated cisplatin kg–1, and
controls were maintained without treatment. Treatments were
administered in mice anesthetized by ip injection of 2,2,2-
tribromoethanol-2-methyl-2-butanol (AvertineH, Sigma Aldrich)
twice (day 0 and 3). Mice were monitored for a maximum of 10
days after first dose to avoid excessive tumor load, and mice weight
and body weight loss were also monitored according to good
laboratory practices to check excessive toxicity of treatments.
Complete tumors of all animals were extracted and weighted at
endpoint of efficacy studies.
Another round of mice was studied for a longer treatment
period. Mice were injected subcutaneously with A549-luc-C8 cells
(Caliper); 0.56106 cells). Tumors were grown over nine days
before starting the treatment. Tumor growth was monitored every
third day by using an in vivo imaging system (IVISH Spectrum,
Caliper), 150 mg D-Luciferine (kg mice)21 was applied ip 5
minutes before scanning. Mice were placed under the CCD
camera and kept under isoflurane anaesthesia (1.5–2% ) during the
measures. Five mice received three ip injections of 1.5 mg cisplatin
kg–1, five mice received the same amount of cisplatin conjugated to
AuNPs and five mice, controls, were maintained without
treatment.
Results and Discussion
AuNP Synthesis and Functionalization
We propose the use of cisplatin attached to 13 nm mercap-
toundecanoic acid (MUA)-capped AuNPs via a pH-dependent
coordination bond, as an efficacious antitumor drug. The bond
between carboxylic acid and Pt is stable under physiologic
conditions, but it is broken at acidic pH. It is well-known that
NPs are internalized via an endocytic pathway [62]. Since the pH
within the endosomes decreases, the release of cisplatin after
internalization by cells is promoted. The active drug (aquated
cisplatin) is able to diffuse out of the endosome and reach the
nucleus. In fact, endosomal release has been previously postulated
as an advanced mode of cellular delivery [63,64]. Such processes,
pH-sensitive release of drugs, have been proposed often in
chemotherapy, for example, by encapsulation of a drug in a pH-
sensitive polymer and subsequent release of the drug in the vicinity
of the tumor, because of the lower pH found there [63]. In our
case, the low pH at the tumor (6–7) does not cause liberation of the
drug. A lower pH (<5) is needed to break the coordination bond
between MUA and cisplatin. Moreover, simultaneous monitoring
of vehicle and drug biodistribution was possible due to the
inorganic nature of both, and this can be correlated to the lack of
systemic toxicity. Tracking both the NPs and the drug will help in
the understanding how the nanocarriers are processed by the
organism.
Conjugates were carefully prepared regarding size, drug
loading, surface charge, and hydrophilicity, as well as stability
even at high concentrations of AuNPs. Cisplatin doses in humans
are around 1–3 mg of cisplatin per kg of body weight. For
treatment in mice (about 30 g body weight) and taking into
account that we can load around 500 cisplatin molecules per NP
(which leads to the highest cisplatin coverage density to our
knowledge in similar NPs), we need to inject about 750 mL of the
conjugates solutions with concentration of NPs as high as 0.5 mM.
The concentration is a serious issue since larger volumes cannot be
injected into the animals, and we can hardly further increase
conjugate concentration without compromising colloidal stability.
Biocompatible sodium citrate AuNPs were synthesized with a
narrow size distribution (13.361.9 nm) and then modified with a
MUA self-assembled monolayer (SAM) and concentrated by a
destabilization–precipitation–resuspension process (Figure 2).
Briefly, glycine buffer was added to decrease the pH to 2.6 to
protonate MUA carboxylic acids. After removing the supernatant,
Nanoparticles for Detoxifying Antitumoral Drugs
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MUA-capped AuNPs were resuspended in tricine buffer at pH 8
concentrating the NPs up to 2.7561014 NP mL–1 to attain
reasonable concentrations for the in vivo studies. The MUA SAM
provided not only electrostatic stability to the system (f-Potential: –
48.5 mV), but carboxylic groups for further linkage to
[Pt(H2O)2(NH3)2]
2+ (aquated cisplatin). It is known that following
cisplatin ([PtCl2(NH3)2]) administration the chloride ligands are
slowly replaced by water molecules, in a process termed aquation.
The aqua ligands in the resulting [PtCl(H2O)(NH3)2]
+ and
[Pt(H2O)2(NH3)2]
2+ are more labile than Cl–, activating the drug
and allowing the platinum atom to bind to bases on DNA [39].
The [Pt(H2O)2(NH3)2]
2+ solution is obtained by adding a solution
of AgNO3 to commercial cisplatin [Pt(Cl)2(NH3)2] to promote the
exchange of Cl– for H2O ligands. After purification by recrystal-
lization-washing steps, the solid [Pt(H2O)2(NH3)2] (NO3)2 was
obtained and dissolved in water before use. It is important to work
with the aquated form of cisplatin since H2O is a better leaving
group than Cl– and allows formation of coordination bonds
between the Pt molecule and the deprotonated MUA carboxylic
groups on the NP, otherwise, the commercial cisplatin molecule
will not bind covalently [60]. In our configuration, the reactive
part of the drug is protected, which leaves the inert NH3 moieties
exposed to the exterior. Thus, the drug is protected against plasma
deactivation. pH control is critical during the whole conjugation
process: the pKa value of a MUA SAM is reported to be between
6–8 [65], therefore the working pH must be above this value to
ensure colloidal stability. However, at higher pH values, aqua
ligands of the aquated cisplatin can undergo deprotonation to give
hydroxo complexes that are less reactive (pKa1<5.5, pKa2<7.3)
[66]. Since the hydroxylation reaction is slow at pH,9, working at
pH 8.3 ensures both colloidal stability and formation of the
conjugate. Otherwise the conjugate would lose electrostatic
stability (at pH,pKa of MUA) or cisplatin would be unable to
form a coordination bond (at pH.9) and it would be electrostat-
ically absorbed, and immediately released when dispersed in high-
ionic-strength media such as biological fluids [60].
To achieve the maximum loading of cisplatin without compro-
mising colloidal stability, aquated cisplatin was added in excess.
The reaction was stopped by removing the excess of aquated
cisplatin after 25 minutes by dialysis, when surface charge, as
measured by f-potential, was 230.8 mV (Figure 3d). It is
commonly accepted that values above +/230 are needed to
achieve colloidal stability [67]. This fact is in agreement with our
observations that f-potential values that are less negative than –
25 mV led to destabilization of the AuNPs and precipitation due
to excessive quenching of the negatively charged carboxylic acid
groups by cisplatin. A similar behavior was shown by Craig et al.
when using a PEG linker which has a carboxylic terminal group as
well [55]. Therefore, appropriate cisplatin concentration and
incubation time are crucial to maintain colloidal stability (Figure 3
a, b, c). At the end, the loading of cisplatin on the NP as measured
by inductively coupled plasma mass spectrometry (ICP-MS) was
42.360.8 mg Pt L–1, which represents an approximate loading of
470 cisplatin molecules per NP. Regarding conjugation, it has
been recurrently observed that, in an excess of conjugating
molecule without interfering species, homogeneous and dense
monolayers of self-assembled organic molecules can form rapidly
on the different NP surfaces [68]; therefore it is even more
important to achieve homogeneous partial conjugation. It is likely
that incubation of the AuNP-MUA with an excess of aquated
cisplatin and then stopping the reaction by removing the excess of
cisplatin by dialysis favors the formation of homogenously loaded
conjugates.
When preparing NP solutions for in vivo applications, the
difference between NP conjugation solutions and physiological
media is important; the latter has higher electrolytic concentration
and strongly buffered pH value. In this context, colloidal stability
in physiological media and no loss of drug during its journey
through the body should both be guaranteed for success of the in
vivo targeting [16]. Prior to in vivo experiments, colloidal stability
was assayed in full human blood by dynamic light scattering (DLS)
and UV-Vis spectroscopy. In DLS measurements, no peaks
indicating the presence of aggregates in blood were observed. The
12-nm shift of the AuNPs peak is due to the formation of a protein
corona [11]. Moreover, the UV-Vis spectra of AuNP–cisplatin in
human blood indicated that AuNPs did not aggregate in this
medium. The strength of the coordination bond makes the link
between carrier and drug stable under physiological conditions.
Since this bond is pH sensitive, increasing the [H+] leads to
hydrolysis of the MUA–Pt bonds, releasing the drug in its active
form. Only 5% of the Pt was released from the AuNPs at pH 7.6
after 144 h, while values as high as 40% of the Pt were reached at
pH 4.4, and 67% at pH 3.8 (Figure 4). One could expect that the
presence of different nucleophilic species, as the presence of
protein, would alter the AuNP-MUA-CisPt « AuNP-MUA +
CisPt equilibrium. However, release seems to be independent of
the buffering species, as demonstrated by observation of similar
behaviors in three different pH 4.4 buffers.
Pt Cell Internalization and DNA Accumulation
Low cellular uptake of the drug may limit the efficacy of a
chemotherapeutic treatment [69], therefore cisplatin cellular
uptake and DNA binding were employed as signs of therapeutic
activity. Adenocarcinomic human alveolar basal epithelial cells
(A549) were treated with both free cisplatin and cisplatin
conjugated to AuNPs (AuNP–cisplatin) at the same Pt concentra-
tion (1.7 mg mL–1). A faster uptake and higher cytoplasmatic levels
of Pt were found in the latter case (Figure 5b). When cisplatin was
conjugated to the AuNPs, cellular drug content was up to 300
times higher at short time periods than for free cisplatin, and levels
up to 125 times higher were found in the DNA at 24 h (Figure 5b).
As can be observed in transmission electron microscopy (TEM)
images (Figure 5a), AuNPs mainly reside inside vesicles that evolve
to form late endosomes and endolysosomes (vesicle size and
number of particles per vesicle increase with time). Similar features
were observed by confocal microscopy (Figure S2). These vesicles
provide an acidic environment that promotes the release of
cisplatin from the AuNPs, and its further escape from the
endosomes to continue its journey towards the DNA. Note that
the aquated form of cisplatin, due to its high lability, is expected
not to travel far from the release point before reaching its target or
being deactivated. Interestingly, the mechanism of drug entry into
the cell is modified by conjugation: free cisplatin enters the cell
mainly via passive diffusion through the membrane and by some
transporter-mediated routes (e.g., copper transporters) [39],
whereas cisplatin attached to AuNPs enters via an endocytic
pathway. This active mechanism, together with the cargo effect,
allowed the rapid accumulation of cisplatin. This rapid accumu-
lation of cisplatin may enable us to overcome multidrug-resistance
mechanisms that involve the overexpression of cisplatin efflux [70]
proteins (e.g., P-glycoprotein) or facilitate DNA-repair mecha-
nisms [40]. Additionally, the coating of the carrier with serum
proteins, mainly albumin, may also favor conjugate uptake due to
an overexpression of albumin receptors in tumoral cells [71].
Indeed, this is the claimed strategy for enhanced uptake of
paclitaxel in Abraxane [72].
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Therapeutic Efficiency of AuNP–cisplatin
Animal models are particularly required when assaying the
therapeutic efficiency of NPs as vehicles for drug delivery. Use of a
nanocarrier will lead to an increased blood half-life and a higher
accumulation in the site of action for the drug [73]. Thus, it is
likely that a properly designed nanocarrier should have a better
response in vivo than in vitro, with respect to the free drug in terms
of concentration of active drug in the organ of interest.
Additionally, issues such as tumor penetrability and toxicity might
be modified as well and must be taken into account. One of the
most common models consists of xenografted tumors implanted
subcutaneously in Severely Compromised ImmunoDeficient
(SCID) mice. If tumor progression has to be measured by size
(e.g., using a caliper), initial tumors must be large enough to be
measurable, in which case they are normally poorly irrigated and
even may contain necrotic areas. Newer bioluminescent tech-
niques (e.g. IVIS H) are a good alternative to caliper measurements
because they are more sensitive and therefore work properly with
smaller tumours, but they depend on enzymatic activity. This
technique has been used to follow tumorigenesis and response of
tumors to treatment in animal models, since the expression of a
bioluminescent marker specific of the implanted tumor cells is
supposed to be proportional to the number of living cells [74].
However, environmental factors and therapeutic interferences
may cause some discrepancies between tumor burden and
bioluminescence intensity in relation to changes in proliferative
activity; this must be taken into account along with the differing
individual response to the tumor and the treatments.
In our experiments, 15 tumor-bearing mice were treated with 3
intraperitoneal (ip) injections of saline (control), free cisplatin, or
AuNP–cisplatin. Doses of cisplatin were 1.5 mg cisplatin kg–1 in
both treatments. Note that different concentrations are used
throughout the work. The reason for these differences is the need
to explore three different regimes: Tissue distribution, therapeutic
window, and toxicity. In the first case, the doses are maximized to
ensure detectable levels of gold and platinum in all tissues. For the
therapeutic window, we explored the range of dosages which can
prevent tumor growth effectively while staying in the safety range
for the treatment (note that the treatment time is much longer than
for biodistribution and toxicity). Otherwise, severe cisplatin-
induced toxicity would have led to dead animals and consequently
to the impossibility of comparing treatments. On the other hand,
for the toxicity assays, we treated the animals with higher
concentrations such as are generally used with cisplatin to induce
toxicity in a short period of time. As can be observed in Figure 5d,
the conjugation of cisplatin to the AuNPs does not affect its
therapeutic effect since both the sample treated with free drug and
that with drug conjugated to AuNPs showed no significant
Figure 2. Transmission Electronic Microscopy (TEM) images of MUA-capped AuNPs. (a, b, c) Representative images of AuNPs. Scale bar
represents 1 mm, 200 nm, and 100 nm respectively. (d) A narrow size distribution (13.361.9 nm) of AuNPs is observed. The appearance of the AuNPs
as synthesized and after concentration process is shown in the inset in (a).
doi:10.1371/journal.pone.0047562.g002
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differences in tumor growth, as measured by bioluminescence, and
both treatments showed decreased tumor growth with respect to
the control. In a similar experiment, but starting the treatment
when tumors were large enough to be measurable by caliper, the
same tendencies were maintained (Figure S3). At the end of these
treatments, tumors were extracted and weighed. The average
weight of tumors in both treatments was 0.5960.16 g for free
cisplatin and 0.7660.20 g when conjugated. These values are
significantly lower than those of the control (1.8160.54 g), with a
Student’s t-distribution between the control and the treated mice
with the conjugates of smaller than 0.05 (0.039).
Figure 3. AuNP functionalization. (a) UV-Vis spectroscopy of conjugates with increasing aquated cisplatin concentrations shows that this
concentration should not exceed 0.39 mM to guarantee colloidal stability. (b) When an excess of drug was introduced, the MUA charge became
progressively quenched, which lead to aggregation of AuNPs, as denoted by the red-shift and further intensity decrease of SPR intensity in less than
one hour. (c) Red-shift of the SPR peak at the working conditions: the initial peak of citrate-capped AuNPs shifted from 515 nm to 521.5 nm after
MUA conjugation and to 523 nm after cisplatin conjugation. (d) Time evolution of f-potential after addition of [Pt (H2O)2(NH3)2]
2+ indicates the
quenching of negative charge on the MUA by the formation of a coordination bond between the carboxylic acid group and aquated cisplatin.
Conjugates remained stable at f-potential values more negative than –25 mV. (e) Scheme showing the functionalization steps followed to obtain the
cisplatin delivery system.
doi:10.1371/journal.pone.0047562.g003
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Tumor penetration is known to be a limiting factor for cancer
drug delivery. In fact, this has been recently identified as the major
limitation in solid tumor treatment [75–77]. Despite this fact,
conjugate sizes of around 15 nm have been reported to achieve
good penetration and accumulation in the tumor [24,44].
Obviously, cisplatin is smaller than the NPs and therefore its
penetrability, in principle, could be higher. However the greater
accumulation of active drug when attached to AuNPs (the drug is
protected against deactivation by plasma proteins) and the
possibility of successive treatments (if cisplatin toxicity is clearly
reduced) may overcome the lower penetrability of the vehicles
[75], allowing the progressive erosion of the tumor. Certainly,
these dosing strategies could also be useful in the case of tumor
resistance to cisplatin treatment. Finally, it is also worth noting that
the metallic core of the AuNPs opens up the possibility of
increasing tumor damage by using a combined therapy since they
can efficiently act as photothermal therapeutic agents [2,78] or as
radiosensitizers [79,80] which, together with surgery, are the
common strategies used to treat cancer in the clinic.
Biodistribution in Mice: Correlation of Biodistribution and
Lack of Toxicity
Inside the body, the porous and diffuse frontiers of the different
organs, which are all connected to the blood and lymphatic
systems, have greatly differing transport abilities towards small
molecules and nutrients, large proteins, or cells. Thus, the majority
of drugs are normally transported through the small pores (6–
8 nm) found in the continuous capillaries which are the most
widely distributed throughout the organism [18], which causes
unwanted side effects. For effective therapy, it is necessary to
deliver therapeutic agents selectively to their target sites, avoiding
non-target organs. Such selectivity is key for antitumoral drugs
because of their extreme cytotoxicity. By vehiculating the drug
using a nanocarrier, the distribution of the drug is controlled by
the physicochemical properties of the nanoparticle [4,17,81]
rather than those of the drug. Normally, small molecule drugs (the
majority of drugs) have a short plasma half-life and are rapidly
cleared by the renal system [18], which thereby greatly reduces the
drug’s curative effect. Also, if escaping the kidney, NPs are easily
endocytosed/phagocytosed, generally by circulating monocytes or
fixed macrophages, which leads to their elimination from
circulation and their simultaneous concentration in organs with
high phagocytic activity. Although several factors such as core size
and surface composition influence the fate of the NPs inside the
organism, different types of NPs have been reported to be cleared
within minutes from the bloodstream with a typical final
biodistribution in the spleen, liver, and kidneys [20,45,67,81–
83]. Not only the NPs’ physicochemical properties (e.g., size,
shape, and surface composition) determines the final fate of the
NPs, but an important role is played by the array of serum proteins
attracted by the NPs that form the well-known protein corona [11]
which ultimately confers their biological properties [84]. In this
regard, many studies indicate that particle size and surface
chemistry (coating) govern translocation across epithelial and
endothelial cell layers. In particular, regarding translocation of
NPs, the studies summarized by Mehta et al. [85] and those
performed by Heckel et al. [86] using intravenous administration
of albumin-coated gold nanoparticles in rodents demonstrated
receptor-mediated transcytosis (albumin-binding proteins). Simi-
larly, polystyrene particles of 240 nm translocated across the
alveolus-capillary barrier when coated with lecithin, whereas
uncoated particles did not translocate [87].
In our experiments, groups of 15 SCID human-tumor-bearing
mice were used to assay the biodistribution of both the vehicle and
the drug. The same amount of a high dose of free or AuNP-bound
cisplatin was administrated to the mice (4 mg Pt (kg mice)–1) via
intraperitoneal injection. This route facilitates the traffic of
particles from the peritoneal cavity to the lymphatic system before
the particles finally enter systemic circulation [88], from where
they are distributed to the different organs. The amounts of both
Pt and Au in blood, liver, spleen, heart, brain, lung, kidney, ovary,
and tumor were measured using ICP-MS at 30 min, and 3, 6, and
24 hours after the injection (Figure 6). It is worth noting that from
the crude readings it is impossible to determine if the observed Pt
is still active, inactive bound to proteins, or attached to the NPs
waiting to be activated. Free cisplatin is known to be removed
from the circulation in two steps: an initial rapid renal clearance
(less than 1 h) followed by a slow loss from the circulation of the
cisplatin bound to plasma proteins (hours to days) [46], with less
than about 3% reaching the tumoral cells’ DNA. Since the long-
circulating cisplatin is mainly bound to protein and consequently
deactivated [46], neither significant toxicity nor therapeutic
benefits are expected from it [47]. This rapid clearance of free
cisplatin, which is also observed from all organs in our work, differs
considerably from what is observed in the case of the cisplatin
bound to AuNPs. The amount of Pt in blood sera released from
the AuNP-cisplatin conjugates (AuNPs were removed by centri-
fugation before measuring) was initially negligible (52.1261.9 mg
L–1). However, once the conjugates were processed, mainly by
phagocytic organs (vide infra), there was a slow delayed release of
Pt to blood that reached 932.256343.4 mg L–1 at 24 h. In the rest
of the organs it is common to see an initial decrease in Pt
concentration, from 30 min to 3 hours and then an increase at 6 h
and 24 h, likely of the non-conjugated form as the changes of the
Au/Pt ratios in organs with time seem to indicate (Figure 7); this
shows how the Au and cisplatin split and follow different pathways
after being processed by cells. The higher the ratio, the less free
cisplatin is present. Although the signal from conjugated and non-
conjugated cisplatin is difficult to deconvolute, two different
behaviors are clearly observed: organs where the ratio progres-
sively decreases (those indicated by dashed lines) and organs where
the ratio increases (those indicated by continuous lines). Note that
the organs where this ratio increased are phagocytic organs where
NPs accumulate. From these results we believe that some
Figure 4. Cisplatin release vs. pH in physiological conditions.
(high-ionic-strength media with 20% BSA; BSA = bovine serum albu-
min). At neutral pH the release was almost negligible but it increased at
acidic pH values.
doi:10.1371/journal.pone.0047562.g004
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Figure 5. Cell internalization and accumulation, and therapeutic benefits in vivo. (a) Representative TEM images showing the
internalization of particles at 1, 3, and 24 h. It is clearly shown that AuNPs were entrapped in vesicles that progressively fuse. The cell nucleus
remained free of AuNPs. Scale bars represent 4 mm. (b, left) Cells show greater amounts of Pt when it enters attached to AuNPs than when in free
cisplatin, especially at short time periods. (b, right) The acidic pH value in the endosomes promotes the release of cisplatin. Consequently the DNA
targeting was also considerably improved by AuNP–cisplatin. (c) The colloidal stability is guaranteed in blood where the presence of aggregates is
excluded by DLS. The 12 nm increase is due to the formation of a soft protein corona. (d) Increase in bioluminescence measured by IVIS which is
proportional to the number of living cells in the tumor. 1.5 mg cisplatin (kg mouse)–1 injections were used in both treatments (day 0, 19, and 34).
Arrows indicate injection days. Errors are standard error of the mean (n = 5).
doi:10.1371/journal.pone.0047562.g005
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information regarding how nanocarriers are processed can be
extracted: The stability of the link in blood is proved since the
amount of free drug is initially negligible (in agreement with
previous in vitro tests, Figures 4 and 5c). Then AuNPs-cisplatin start
to accumulate preferentially in the phagocytic organs and are
processed. From there the drug is released again to the systemic
circulation in a process that we call secondary release, as the
primary release is the release of cisplatin in the tumor cells. This
secondary release can be considered an artifact of working with
nanocarriers since it is known that, far away from the magic bullet
concept, NPs are accumulated in phagocytic organs. However,
there is a lack of cisplatin-induced toxicity due to this secondary
release, which can be explained because cisplatin levels in blood
are much lower than the achieved after free drug administration.
Moreover the active form of cisplatin released from the NPs might
be rapidly deactivated by plasma proteins, even faster than
commercial cisplatin is deactivated, since it is more reactive.
Consequently the drug coming from the secondary release is not
expected to have significant therapeutic or toxic effects in our case,
but this process should be taken into account when dealing with
nanocarriers for drug delivery.
A detailed analysis of the biodistribution of the conjugates
showed no evidence of accumulation of Au or Pt in the brain,
heart, or lung other than that coming from the blood present in
these tissues (Figure 6 c, d, e). 13 nm AuNPs are not expected to
cross the blood–brain barrier [82], hence it is not surprising that
the lowest Au content of all the analyzed organs was found in the
brain. In all of these organs the amounts of Pt are 5-10-fold lower
in the treatment with AuNPs-cisplatin than when treated with free
cisplatin. A markedly different behavior was observed in liver and
spleen (Figure 6 f, g) which are responsible for clearance of
nanocarriers [20,45,67,82,83]. In fact, these –together with the
ovary (Figure 6h) – are the only organs in which the Pt contents
were higher in the case of AuNP–cisplatin treatments than for free
cisplatin. These organs are highly phagocytic and will take up the
AuNP–cisplatin conjugates and process them. Macrophages are
found in the organs of the mononuclear phagocytic system (liver
and spleen) as well as in the peritoneum (close to the ovary) and in
the periphery of the kidneys. Accumulation of AuNP–CisPt
conjugates in the ovaries, whose tumor is treated with cisplatin
[38], is probably a consequence of the intraperitoneal adminis-
tration. In fact, this route has been proposed for treatment of
ovarian cancer with nanoparticles since they show a slower
absorption profile into the lymphatic system than that of the free
drug by this administration route [89]. It is also reasonable to think
that in 24 h a significant amount of the conjugates is still in the
peritoneum or lymph nodes, at the beginning of the journey that
they perform during the treatments.
To observe the differential distribution in the measured organs,
we also plot the relative amounts detected normalized to the total
detected amounts at the different times (Figure 8). It is clearly
observed that the cisplatin spared from the kidney seems to end up
in the spleen, which deserves special attention in the case of
vehiculated drugs.
The kidney deserves special consideration due to the high
nephrotoxicity of cisplatin. Here, Pt levels were reduced consid-
erably when AuNP–cisplatin was administered, compared to free
cisplatin (Figure 6 b), at all times. Moreover, the AuNPs that
reached the kidneys were trapped by peripheral macrophages,
which thus diminished the potential damage induced by cisplatin
(Figure 9g) as histopathology studies show (Figure 9 a, b, c).
Histological analysis of the kidneys after treatment with free
cisplatin and AuNP–cisplatin (21 days, 3 doses of 5 mg cisplatin
(kg mice)–1 in both cases) revealed a lack of damage in the latter
case, while in the case of free cisplatin, the kidneys were severely
damaged. The morphological changes were consistent with
cisplatin-induced acute nephrosis [90]. In addition to the observed
absence of kidney damage in the mice treated with AuNP-CisPt,
biochemical analysis did not show renal (blood urea nitrogen and
creatinine levels) or liver (transaminases) damage (Table S1). What
we observed was a modest lower leukocytes count for both
treatments, slightly enhanced when the cisplatin is conjugated.
Also there was no sign of anemia, and an increase of platelets in
the case when the conjugates were employed (Figure 10 b).
When comparing the weight of the differently treated organs,
clear reduction of the kidney weight was observed in the case of
mice treated with free cisplatin; this is consistent with the observed
histological damage. A significant increase of weight of the spleen
treated with NPs (Figure 10 a) was also seen. To exclude any
spleen toxicity induced by the nanoparticles, histological analysis
of the spleen was also performed. Representative microscopy
images of spleen slices of the control, the sample treated with free
cisplatin, and a sample from the AuNP-cisplatin treatment do not
show any adverse effect of the treatments in this organ; no damage
or inflammation (Figure 9 d, e, f). Pathologists observed no
significant differences in morphology between control, free
cisplatin, and AuNP-cisplatin treated samples. In the case of
AuNPs one could observe them accumulated in macrophages in
the periphery of the spleen, as was previously observed in the
kidneys. When using the conjugates, no morphological changes
were observed, but a diffuse hyperplasia was observed, which
manifested in the weight increase; the most significant alteration
was the increased number of megacariocytes (platelet precursors),
which can be related to the observed increase of circulating
platelets. The diffuse hyperplasia of the red pulp was attributed to
extramedullary haematopoiesis, likely after anemia due to the
cisplatin treatment. Both anemia and hyperplasia are temporary
and sequential and are expected to remedy themselves as cisplatin
is being processed.
Lack of systemic toxicity in long-term treatment is normally
assayed by measuring the body-weight loss from three groups of
mice that received no treatment (control), free cisplatin, or AuNP–
cisplatin (three injections of 5 mg cisplatin (kg mouse)–1 in both
cases; in a 13 day experiment; Figure 9 h). After the initial weight
loss in both treatments, weight recovery was most evident in mice
treated with AuNP-cisplatin. More significantly, after the second
dose, mice treated with free cisplatin decreased in weight more
dramatically and showed no signs of recovery, which can be
attributed to the cumulative toxic effects of cisplatin [91], whilst
the mice treated with AuNP-cisplatin experienced a smaller weight
decrease, a rapid recovery, and no evidence of any memory effects.
Although the lack of cisplatin-induced toxicity has been proven
here when cisplatin is attached to the nanoparticles, a deeper
understanding of nanoparticles’ inherent toxicity might be
required before this technology can be used in clinical trials.
There is controversy regarding the in vivo toxicity of NPs and the
parameters that play a role in the NP-induced toxicity [92]. Some
work found no toxic signals after AuNP administration [93] or
small alterations in the biochemical markers due to metabolization
of the AuNPs, or indicating a temporal inflammation [94]. On the
other hand, it is believed that the dysfunction of major organs can
be related to the presence of NPs at the site of abnormalities. For
that reason, there are many studies regarding toxicity of AuNPs in
spleen and liver, which are generally accepted to be the organs
with the highest accumulation of AuNPs. Liver toxicity, when
found, seems to be associated to an hyperplasia of Kupffer cells
that induce an acute inflammation with neutrophil influx [82].
This acute inflammation is a transient response due to insult of
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Figure 6. Biodistribution of Au and Pt arising from the treatment with free cisplatin (quantification of Pt, black) and AuNP–cisplatin
(quantification of Pt and gold, black and blue respectively). The amounts of Pt and Au were analyzed in relevant organs at 0.5, 3, 6, and 24 h
after injection by ICP-MS. Errors are standard error of the mean (n = 3). See text for extended analysis of this data.
doi:10.1371/journal.pone.0047562.g006
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AuNPs, however apoptosis and necrosis of hepatocytes, as well as
accumulation of AuNPs, could be related to toxic effects [95].
Regarding the spleen, macrophages of the periphery seem to be
involved in the uptake of NPs by this organ, thus leading to a
temporal inflammation of the spleen. However, in other cases a
loss of weight has been observed after intravenous administration
[96]. White pulp aberration has been also observed [97]. No
general trend can be extracted from the current literature, but it is
clear that there are some parameters that have to be taken into
account before using AuNPs as a vehicle for medical applications:
i) size of the vehicle, since it will determine the clearance rate and
the biodistribution [97]; ii) surface composition; it has been seen
that by changing the surface composition of AuNPs the
toxicological profile might be different [98]; iii) dose and
administration route obviously will play a role in the potential
toxicity. Here it is important to remark that the physicochemical
properties that will influence the biological activity of the
nanoparticle should be assayed in physiological conditions, since
a change of these properties could happen in complex media such
as biological fluids. Therefore for every AuNP-conjugate, a
toxicology study must be done to prove its usability in medical
applications.
Conclusions
AuNP–cisplatin colloids were designed and prepared to be
highly stable in physiological conditions to ferry the antineoplastic
drug cisplatin towards its target, sparing the kidney. The conjugate
has a size and a surface charge similar to those of proteins in serum
to ensure its vehicular properties in physiological conditions,
without interfering with cisplatin’s mechanism of action. This
conjugation translates into a greater uptake and better DNA
targeting of the drug, as proven by the in vitro experiments. In vivo,
the vehiculization of the drug using AuNPs dramatically modified
its biodistribution in mice, avoiding organs where cisplatin is
known to be toxic while maintaining therapeutic benefits.
Moreover, the drug made the journey through the body protected
against deactivation by plasma proteins, and thanks to the pH-
sensitive link, the active form of cisplatin was only released after
Figure 7. Time evolution of the ratio Au/Pt in different organs.
Two different behaviors were observed: the one indicated by
continuous lines (organs in which tissue macrophages are present)
shows an increase of this ratio at the first times which indicates a
depletion of Pt, likely due to the secondary release explained in the
main text. Consequently, the other organs which are irrigated by
continuous capillaries can take this Pt up and therefore the ratio
decreases.
doi:10.1371/journal.pone.0047562.g007
Figure 8. Biodistribution in function of the percentage of found elements for every organ at the four assayed times.
doi:10.1371/journal.pone.0047562.g008
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cell internalization. It is also shown that any drug that did not
reach the target was mainly processed by the liver and spleen,
which allowed the delayed release of cisplatin. However this
cisplatin is centered at the release point and rapidly deactivated
(aquated cisplatin is more reactive than standard cisplatin). The
pharmacological modifications –decrease in toxicity but not in
therapeutic benefits– may also allow prolonged treatment.
In summary, the active mechanism of cisplatin, its pharmaco-
dynamics, and binding to DNA and impedance of cell division, are
not modified by its attachment to and vehiculation with a gold NP,
while its pharmacokinetics and biodistribution are significantly
modified.The major contribution of nanotechnology for delivering
very effective drugs, such as cisplatin, is not to increase their
therapeutic capacity, but better direct the drug to its target.
Therefore, before the old dream of the magic bullet can be
attained, a significant decrease of the drug’s toxicity, achieved here
by modifying its pharmacokinetics properties, would represent a
breakthrough in cancer treatment.
Figure 9. Toxicity of cisplatin. The appearance of histopathological changes in the proximal tubuli is evidence of nephrotoxicity. (a) Normal
appearance of kidney section of control animals and (b) mice treated with AuNP-cisplatin. (c) Proximal tubular degeneration of animals taking high-
dose cisplatin. Histological slides of spleen showed no signs of pathology in (d) control, (e) AuNPs-cisplatin, and (f) free cisplatin treatments. (g) AuNPs
that reached the kidneys were trapped by peripheral macrophages. (Magnifications are x40 in a-f and x20 in d). (h) Body weight change of control
mice and mice that received the same amount of free cisplatin or conjugated to AuNPs (4 mg kg–1, days 0 and 8). The arrows indicate the day of
injection. Loss of weight and further recovery capacity is a clinical test to assay systemic toxicity. Errors are standard error of the mean (n = 5). Scale
bars represent 100 mm in a, b, c and 200 mm in d.
doi:10.1371/journal.pone.0047562.g009
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Supporting Information
Figure S1 Different cellular internalization of conjugate
and free drug (not drawn to scale). AuNPs-cisplatin are
internalized via an endocytic pathway, hence cisplatin is only
released at the acidic pH of the endosomes. Moreover AuNPs
protect the drug from being deactivated by plasma proteins. Free
cisplatin mainly enters via diffusion through the cell membrane.
Inside the cytoplasm the interchange of Cl2 for H2O molecules
takes place and the active drug is then formed.
(TIFF)
Figure S2 Confocal microscopy of A549 treated with
AuNP-cisplatin. Cells were incubated with AuNP-cisplatin for
(a) 30 min, (b) 1 h, (c) 3 h, and (d) 24 h. Afterwards, they were
processed by staining nuclear DNA with DAPI, and a-tubulin
microtubules with monoclonal mouse anti a-tubulin antibody and
goat anti mouse antibody conjugated with Alexa 488. Nanopar-
ticles appear as red dots because of their ability to scatter light
[99]. A LEICA TCS SP2 AOBS Spectral Confocal system was
used for image processing. There is evidence of internalization
with time, and no nanoparticles were observed in the nucleus.
Also, as time passes and nanoparticles are processed, deposits of
NPs are observed. Some of those extracellular deposits may also
occur due to the cell processing for microscopy.
(TIFF)
Figure S3 Therapeutic efficiency and body weight
change of short treatment. (a) Differences in tumor volumes
measured by caliper after two consecutive injections (day 0 and 3)
of 3 and 1.5 mg cisplatin (kg mouse)–1 each of free cisplatin and
AuNP–cisplatin, respectively. The antitumor activity of cisplatin
was maintained after the drug was conjugated to the AuNPs.
Tumor catch-up was also observed. (b) A large body-weight loss
was caused by the high dose of free cisplatin (6 mg kg21). This loss
was not observed in the case of AuNPs-cisplatin. However the
primary effect was not significantly different in both treatments.
(TIFF)
Table S1 Analysis of relevant biochemical markers.
Aspartate transaminase (AST) and Alanine transaminase (ALT)
levels indicate that there is no evidence of liver dysfunction. The
renal function is usually determined by the levels of Blood Urea
Nitrogen (BUN) and creatinine. Although the BUN seems to be
higher than levels reported in other works [100], it should be noted
that there is no difference between the control and treatment with
AuNPs-cisplatin. Total protein and albumin are also indicators of
hepatic function.
(PDF)
Text S1 Experimental Details.
(DOCX)
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Figure 10. Kidney and spleen weights and hematology. (a) Weight of kidneys decreased only in the case of free cisplatin treatment, which
agrees the previously observed cisplatin-induced toxicity. On the other hand, spleen weight increased in the case of AuNPs-cisplatin treatment, likely
due to a temporal hyperplasia of the red pulp. (b) Leukocytes, platelets, and erythrocytes were also quantified and the organ showed no signs of
anemia, but an increased number of platelets in the AuNPs-cisplatin, which is likely related to the hyperplasia of the spleen. * P,0.05, ** P,0.001.
doi:10.1371/journal.pone.0047562.g010
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